Drug Trial Radar · NCT07594236
Phase 1 Study of C.001 in Retinal Degeneration
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Apr 7, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Cellio Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- California Institute for Regenerative Medicine (CIRM)
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner. The primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.
Conditions
- Geographic Atrophy
- Stargardt Disease
- RPE-mediated Maculopathy
- Age Related Macular Degeneration
Interventions
InjectionBiological
C.001 administered once via subretinal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Ocular and Systemic Adverse EventsTime frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Retina Vision Consultants
Beverly Hills, California · Recruiting
Palo Alto Medical Foundation
Palo Alto, California · Not yet recruiting
Retinal Consultants Medical Group
Sacramento, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.